LublinFDCoetzeeTCohenJA, et al. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology2020; 94: 1088–1092.
2.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–911.
3.
LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
4.
Katz SandIKriegerSFarrellC, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler2014; 20: 1654–1657.
5.
KuhlmannTMocciaMCoetzeeT, et al. Multiple sclerosis progression: Time for a new mechanism-driven framework. Lancet Neurol2023; 22: 78–88.
6.
KapposLWolinskyJSGiovannoniG, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA neurology2020; 77: 1132–1140.
7.
LublinFDHaringDAGanjgahiH, et al. How patients with multiple sclerosis acquire disability. Brain2022; 145: 3147–3161.
8.
TurCCarbonell-MirabentPCobo-CalvoA, et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol2023; 80: 151–160.
9.
SatyanarayanSCutterGKriegerS, et al. The impact of relapse definition and measures of durability on MS clinical trial outcomes. Mult Scler2023; 29: 568–575.
10.
BrownleeWJAltmannDRPradosF, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain2019; 142: 2276–2287.
11.
ChungKKAltmannDBarkhofF, et al. A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann Neurol2020; 87: 63–74.
12.
KassaRMSechiEFlanaganEP, et al. Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult Scler2021; 27: 895–902.
13.
KriegerSCSumowskiJ. New insights into multiple sclerosis clinical course from the topographical model and functional reserve. Neurol Clin2018; 36: 13–25.
